\thispagestyle {empty}
\contentsline {chapter}{\numberline {1}Review of computational drug repositioning approaches}{15}{chapter.1}
\contentsline {section}{\numberline {1.1}Relevance of drug repositioning}{16}{section.1.1}
\contentsline {subsection}{\numberline {1.1.1}Opportunities for finding new indications}{17}{subsection.1.1.1}
\contentsline {subsection}{\numberline {1.1.2}Drug repositioning faces legal and scientific challenges}{20}{subsection.1.1.2}
\contentsline {section}{\numberline {1.2}Drug repositioning and indication discovery: success stories}{21}{section.1.2}
\contentsline {subsection}{\numberline {1.2.1}Sildenafil: repositioning from clinical side-effects}{22}{subsection.1.2.1}
\contentsline {subsection}{\numberline {1.2.2}Thalidomide: repositioning a hazardous drug}{23}{subsection.1.2.2}
\contentsline {subsection}{\numberline {1.2.3}Raloxifene: expanding the application line}{24}{subsection.1.2.3}
\contentsline {section}{\numberline {1.3}Computational approaches towards drug repositioning}{25}{section.1.3}
\contentsline {subsection}{\numberline {1.3.1}Chemical structure-based approaches}{26}{subsection.1.3.1}
\contentsline {subsection}{\numberline {1.3.2}Gene expression and functional genomics-based approaches}{29}{subsection.1.3.2}
\contentsline {subsection}{\numberline {1.3.3}Protein structure and molecular docking-based approaches}{32}{subsection.1.3.3}
\contentsline {subsection}{\numberline {1.3.4}Phenotype and side-effect-based approaches}{34}{subsection.1.3.4}
\contentsline {subsection}{\numberline {1.3.5}Genetic variation-based approaches}{37}{subsection.1.3.5}
\contentsline {subsection}{\numberline {1.3.6}Disease network-based approaches}{38}{subsection.1.3.6}
\contentsline {subsection}{\numberline {1.3.7}Machine learning and concepts combination approaches}{41}{subsection.1.3.7}
\contentsline {subsection}{\numberline {1.3.8}Summary}{43}{subsection.1.3.8}
\contentsline {section}{\numberline {1.4}Thesis: biological process and molecular function for drug repositioning}{47}{section.1.4}
\contentsline {subsection}{\numberline {1.4.1}Rationale}{47}{subsection.1.4.1}
\contentsline {subsection}{\numberline {1.4.2}Towards the specification, implementation and analysis}{49}{subsection.1.4.2}
\contentsline {subsubsection}{\numberline {1.4.2.1}Chapter 2 - Description logics and biomedical knowledge (Specification)}{50}{subsubsection.1.4.2.1}
\contentsline {subsubsection}{\numberline {1.4.2.2}Chapter 3 - The Functional Therapeutic Chemical Classification System (Implementation)}{50}{subsubsection.1.4.2.2}
\contentsline {subsubsection}{\numberline {1.4.2.3}Chapter 4 - Systematic drug repositioning analysis}{51}{subsubsection.1.4.2.3}
\contentsline {subsubsection}{\numberline {1.4.2.4}Chapter 5 - Outlook and future work}{51}{subsubsection.1.4.2.4}
\contentsline {chapter}{\numberline {2}Description logics and biomedical knowledge (Specification)}{53}{chapter.2}
\contentsline {section}{\numberline {2.1}Introduction}{54}{section.2.1}
\contentsline {section}{\numberline {2.2}Biomedical knowledge}{55}{section.2.2}
\contentsline {subsection}{\numberline {2.2.1}Contemporary formalism in biomedical sciences}{55}{subsection.2.2.1}
\contentsline {subsubsection}{\numberline {2.2.1.1}Formalism varies among natural sciences}{55}{subsubsection.2.2.1.1}
\contentsline {subsubsection}{\numberline {2.2.1.2}Organisms as complex machines}{58}{subsubsection.2.2.1.2}
\contentsline {subsection}{\numberline {2.2.2}Requirements for biomedical knowledge formalisation}{61}{subsection.2.2.2}
\contentsline {subsubsection}{\numberline {2.2.2.1}Mathematical framework}{61}{subsubsection.2.2.2.1}
\contentsline {subsubsection}{\numberline {2.2.2.2}Definitions}{62}{subsubsection.2.2.2.2}
\contentsline {subsubsection}{\numberline {2.2.2.3}Hierarchies and abstraction}{62}{subsubsection.2.2.2.3}
\contentsline {subsubsection}{\numberline {2.2.2.4}Distributed and scalable}{63}{subsubsection.2.2.2.4}
\contentsline {subsubsection}{\numberline {2.2.2.5}Molecular dynamism}{64}{subsubsection.2.2.2.5}
\contentsline {section}{\numberline {2.3}Description logics for biomedical knowledge representation}{65}{section.2.3}
\contentsline {subsection}{\numberline {2.3.1}Problems addressed by description logics}{65}{subsection.2.3.1}
\contentsline {subsection}{\numberline {2.3.2}Expressivity and complexity}{68}{subsection.2.3.2}
\contentsline {subsection}{\numberline {2.3.3}DLs' components and relation to life sciences}{70}{subsection.2.3.3}
\contentsline {subsubsection}{\numberline {2.3.3.1}Description logics entities}{70}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Named Individuals}\\}{70}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Concepts}\\}{71}{subsubsection.2.3.3.1}
\contentsline {paragraph}{\textbf {Roles}\\}{71}{figure.caption.25}
\contentsline {subsubsection}{\numberline {2.3.3.2}Axioms}{72}{subsubsection.2.3.3.2}
\contentsline {paragraph}{\textbf {Assertional axioms (ABox)}\\}{72}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept assertion\\}{73}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Role assertion\\}{73}{subsubsection.2.3.3.2}
\contentsline {paragraph}{\textbf {Terminological axioms (TBox)}\\}{73}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept inclusion ($ \sqsubseteq $)\\}{73}{subsubsection.2.3.3.2}
\contentsline {subparagraph}{Concept equivalence ($ \equiv $)\\}{73}{figure.caption.26}
\contentsline {paragraph}{\textbf {Relational axioms (RBox)}\\}{74}{figure.caption.26}
\contentsline {subparagraph}{Role inclusion ($ \sqsubseteq $)\\}{74}{figure.caption.26}
\contentsline {subsubsection}{\numberline {2.3.3.3}Constructors}{75}{subsubsection.2.3.3.3}
\contentsline {paragraph}{\textbf {Intersection ($ \sqcap $)}\\}{75}{figure.caption.27}
\contentsline {paragraph}{\textbf {Existential Restriction ($ \exists $)}\\}{76}{figure.caption.27}
\contentsline {paragraph}{\textbf {Role composition ($ \circ $)}\\}{77}{figure.caption.28}
\contentsline {subsection}{\numberline {2.3.4}Reasoning services}{78}{subsection.2.3.4}
\contentsline {subsection}{\numberline {2.3.5}The Web Ontology Language 2 (OWL2)}{80}{subsection.2.3.5}
\contentsline {section}{\numberline {2.4}Implementation with life-science information}{81}{section.2.4}
\contentsline {subsection}{\numberline {2.4.1}Integration with biomedical ontologies}{81}{subsection.2.4.1}
\contentsline {subsubsection}{\numberline {2.4.1.1}Open Biomedical Ontologies (OBO)}{81}{subsubsection.2.4.1.1}
\contentsline {subsubsection}{\numberline {2.4.1.2}Approximations and assumptions}{83}{subsubsection.2.4.1.2}
\contentsline {subsection}{\numberline {2.4.2}Integration with databases}{86}{subsection.2.4.2}
\contentsline {subsection}{\numberline {2.4.3}Brain library - implementing programmatic solutions}{88}{subsection.2.4.3}
\contentsline {section}{\numberline {2.5}Summary}{90}{section.2.5}
\contentsline {chapter}{\numberline {3}The Functional Therapeutic Chemical Classification System (Implementation)}{93}{chapter.3}
\contentsline {section}{\numberline {3.1}Introduction}{94}{section.3.1}
\contentsline {section}{\numberline {3.2}Method and definitions}{97}{section.3.2}
\contentsline {subsection}{\numberline {3.2.1}Source code}{97}{subsection.3.2.1}
\contentsline {subsection}{\numberline {3.2.2}Categories creation}{98}{subsection.3.2.2}
\contentsline {subsubsection}{\numberline {3.2.2.1}Mode of Action categories}{98}{subsubsection.3.2.2.1}
\contentsline {subsubsection}{\numberline {3.2.2.2}Mechanism of Action categories}{99}{subsubsection.3.2.2.2}
\contentsline {subsection}{\numberline {3.2.3}Equivalent definitions}{99}{subsection.3.2.3}
\contentsline {subsubsection}{\numberline {3.2.3.1}Regulatory pattern}{99}{subsubsection.3.2.3.1}
\contentsline {subsubsection}{\numberline {3.2.3.2}Functional pattern}{102}{subsubsection.3.2.3.2}
\contentsline {subsection}{\numberline {3.2.4}Data integration}{103}{subsection.3.2.4}
\contentsline {subsubsection}{\numberline {3.2.4.1}Drugbank}{103}{subsubsection.3.2.4.1}
\contentsline {subsubsection}{\numberline {3.2.4.2}Gene Ontology Annotations (GOA)}{106}{subsubsection.3.2.4.2}
\contentsline {subsection}{\numberline {3.2.5}Knowledge base classification}{106}{subsection.3.2.5}
\contentsline {subsection}{\numberline {3.2.6}Evaluation methodology}{107}{subsection.3.2.6}
\contentsline {subsubsection}{\numberline {3.2.6.1}Evaluation Points}{108}{subsubsection.3.2.6.1}
\contentsline {subsubsection}{\numberline {3.2.6.2}True Positives}{109}{subsubsection.3.2.6.2}
\contentsline {subsubsection}{\numberline {3.2.6.3}False Negatives}{109}{subsubsection.3.2.6.3}
\contentsline {subsubsection}{\numberline {3.2.6.4}False Positives}{109}{subsubsection.3.2.6.4}
\contentsline {subsubsection}{\numberline {3.2.6.5}Precision}{109}{subsubsection.3.2.6.5}
\contentsline {subsubsection}{\numberline {3.2.6.6}Recall}{109}{subsubsection.3.2.6.6}
\contentsline {subsection}{\numberline {3.2.7}Semantic similarity}{110}{subsection.3.2.7}
\contentsline {subsection}{\numberline {3.2.8}Mode of action similarity against indication}{110}{subsection.3.2.8}
\contentsline {subsection}{\numberline {3.2.9}Knowledge base specification}{111}{subsection.3.2.9}
\contentsline {subsubsection}{\numberline {3.2.9.1}Core FTC classes}{111}{subsubsection.3.2.9.1}
\contentsline {paragraph}{molecular function}{111}{subsubsection.3.2.9.1}
\contentsline {paragraph}{biological process}{111}{subsubsection.3.2.9.1}
\contentsline {paragraph}{Protein}{111}{subsubsection.3.2.9.1}
\contentsline {paragraph}{Drug}{112}{subsubsection.3.2.9.1}
\contentsline {paragraph}{therapeutic agent}{112}{subsubsection.3.2.9.1}
\contentsline {paragraph}{DrugBank compound}{112}{subsubsection.3.2.9.1}
\contentsline {subsubsection}{\numberline {3.2.9.2}Core FTC properties}{112}{subsubsection.3.2.9.2}
\contentsline {paragraph}{part-of}{112}{subsubsection.3.2.9.2}
\contentsline {paragraph}{has-part}{113}{subsubsection.3.2.9.2}
\contentsline {paragraph}{regulates}{113}{subsubsection.3.2.9.2}
\contentsline {paragraph}{negatively-regulates}{113}{subsubsection.3.2.9.2}
\contentsline {paragraph}{positively-regulates}{113}{subsubsection.3.2.9.2}
\contentsline {paragraph}{involved-in}{114}{subsubsection.3.2.9.2}
\contentsline {paragraph}{has-function}{114}{subsubsection.3.2.9.2}
\contentsline {paragraph}{perturbs}{114}{subsubsection.3.2.9.2}
\contentsline {paragraph}{negatively-perturbs}{115}{subsubsection.3.2.9.2}
\contentsline {paragraph}{postively-perturbs}{115}{subsubsection.3.2.9.2}
\contentsline {section}{\numberline {3.3}The classification}{115}{section.3.3}
\contentsline {section}{\numberline {3.4}Evaluation}{118}{section.3.4}
\contentsline {section}{\numberline {3.5}Exploration}{119}{section.3.5}
\contentsline {subsection}{\numberline {3.5.1}Polypharmacology spectrum}{119}{subsection.3.5.1}
\contentsline {subsection}{\numberline {3.5.2}Drugs with similar functions have similar indications}{121}{subsection.3.5.2}
\contentsline {section}{\numberline {3.6}Discussion}{126}{section.3.6}
\contentsline {subsection}{\numberline {3.6.1}Biological assumptions}{127}{subsection.3.6.1}
\contentsline {subsection}{\numberline {3.6.2}Interpreting the evaluation}{128}{subsection.3.6.2}
\contentsline {section}{\numberline {3.7}Summary}{129}{section.3.7}
\contentsline {chapter}{\numberline {4}Systematic drug repositioning analysis}{131}{chapter.4}
\contentsline {section}{\numberline {4.1}Introduction}{132}{section.4.1}
\contentsline {section}{\numberline {4.2}Structure, function and indication of drugs}{133}{section.4.2}
\contentsline {subsection}{\numberline {4.2.1}Structural descriptor selection}{133}{subsection.4.2.1}
\contentsline {subsection}{\numberline {4.2.2}Dissimilar structures have dissimilar functions}{136}{subsection.4.2.2}
\contentsline {subsection}{\numberline {4.2.3}The more specific an indication is, the more similar the function and structure are}{140}{subsection.4.2.3}
\contentsline {subsection}{\numberline {4.2.4}Isolation of drug repositioning hypotheses}{148}{subsection.4.2.4}
\contentsline {section}{\numberline {4.3}Open drug repositioning hypotheses}{150}{section.4.3}
\contentsline {subsection}{\numberline {4.3.1}Relationship between therapeutic areas}{151}{subsection.4.3.1}
\contentsline {subsection}{\numberline {4.3.2}Drug repositioning for hypertension and the cardiovascular system}{156}{subsection.4.3.2}
\contentsline {subsubsection}{\numberline {4.3.2.1}Antihypertensives}{158}{subsubsection.4.3.2.1}
\contentsline {subsubsection}{\numberline {4.3.2.2}Calcium channel blockers}{161}{subsubsection.4.3.2.2}
\contentsline {subsubsection}{\numberline {4.3.2.3}Adrenergic receptor antagonists}{164}{subsubsection.4.3.2.3}
\contentsline {subsubsection}{\numberline {4.3.2.4}Alpha-2 agonists}{166}{subsubsection.4.3.2.4}
\contentsline {subsubsection}{\numberline {4.3.2.5}Diuretics}{167}{subsubsection.4.3.2.5}
\contentsline {subsubsection}{\numberline {4.3.2.6}Renin-angiotensin system}{169}{subsubsection.4.3.2.6}
\contentsline {paragraph}{\textbf {Angiotensin-converting enzyme (ACE) inhibitors}\\}{170}{figure.caption.77}
\contentsline {paragraph}{\textbf {Angiotensin II receptor antagonists}\\}{171}{figure.caption.77}
\contentsline {paragraph}{\textbf {Renin inhibitors}\\}{171}{figure.caption.77}
\contentsline {paragraph}{\textbf {Aldosterone receptor antagonists}\\}{172}{figure.caption.77}
\contentsline {subsubsection}{\numberline {4.3.2.7}Peripheral vasodilators}{172}{subsubsection.4.3.2.7}
\contentsline {subsection}{\numberline {4.3.3}Repositioning for Alzheimer's disease}{175}{subsection.4.3.3}
\contentsline {section}{\numberline {4.4}Summary}{178}{section.4.4}
\contentsline {section}{\numberline {4.5}Methods}{180}{section.4.5}
\contentsline {subsection}{\numberline {4.5.1}Structural fingerprints calculation}{180}{subsection.4.5.1}
\contentsline {subsection}{\numberline {4.5.2}Structural similarity between drugs}{180}{subsection.4.5.2}
\contentsline {subsection}{\numberline {4.5.3}Agreement between fingerprinting methodologies}{181}{subsection.4.5.3}
\contentsline {subsection}{\numberline {4.5.4}Kernel density plots}{181}{subsection.4.5.4}
\contentsline {subsection}{\numberline {4.5.5}Web application related to drug repositioning hypotheses}{182}{subsection.4.5.5}
\contentsline {subsection}{\numberline {4.5.6}Filtering of drug repositioning hypotheses}{183}{subsection.4.5.6}
\contentsline {subsection}{\numberline {4.5.7}Filtering of relationships between therapeutic areas}{183}{subsection.4.5.7}
\contentsline {chapter}{\numberline {5}Outlook and future work}{185}{chapter.5}
\contentsline {section}{\numberline {5.1}Work performed in the context of the drug discovery process}{186}{section.5.1}
\contentsline {section}{\numberline {5.2}Comparison against functional genomics}{187}{section.5.2}
\contentsline {section}{\numberline {5.3}Biomedical knowledge: towards a simpler representation}{188}{section.5.3}
\contentsline {section}{\numberline {5.4}Off-label uses and clinical drug repositioning}{190}{section.5.4}
\contentsline {chapter}{Bibliography}{209}{chapter*.83}
\contentsline {chapter}{\numberline {A}Glossary}{211}{appendix.A}
\contentsline {chapter}{\numberline {B}Abbreviations}{213}{appendix.B}
\contentsline {chapter}{\numberline {C}Peer-reviewed publications}{215}{appendix.C}
\contentsline {chapter}{\numberline {D}Side projects}{219}{appendix.D}
\contentsline {chapter}{\numberline {E}Teaching and editorial work}{221}{appendix.E}
\contentsline {section}{\numberline {E.1}Teaching experiences}{221}{section.E.1}
\contentsline {section}{\numberline {E.2}Editorial work}{222}{section.E.2}
